A Study of KL590586 in Patients With Advanced Solid Tumors
Status:
Enrolling by invitation
Trial end date:
2025-05-30
Target enrollment:
Participant gender:
Summary
An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability,
Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With
Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.